0000358654
Donate

Reimbursement status:
Full reimbursement

Cancer: Lymphocytic leukaemia

Indication:

Treatment of acute lymphoblastic leukaemia (ALL) in paediatric patients who have relapsed or are refractory after receiving at least two prior regimens and where there is no other treatment option anticipated to result in a durable response. Safety and efficacy have been assessed in studies of patients ≤ 21 years old at initial diagnosis.

Reimbursement information:

EPAR/SmPC

Drug programme

Details

ATC category :
L01BB
L01BB Purine analogues
EMA approval status :
Approved
EMA approval date :
2006-05-29
EMA conditional? :
No
EMA orphan? :
No
EMA biological? :
No